Floxuridine for Injection
»Floxuridine for Injection is lyophilized Floxuridine suitable for intraarterial infusion.It contains not less than 90.0percent and not more than 110.0percent of the labeled amount of C9H11FN2O5.
Packaging and storage— Preserve in Containers for Injectionsas described under Injections á1ñ,protected from light.Store containers of constituted Floxuridine for Injection under refrigeration for not more than 2weeks.
Constituted solution— It meets the requirements for Constituted Solutionsunder Injections á1ñ.
Identification—
Solution— Use Assay preparation.
B: It responds to Identificationtest Cunder Floxuridine.
Pyrogen— It meets the requirements of the Pyrogen Test á151ñ,the test dose being 0.50mLper kg of a solution prepared by dilution of Floxuridine for Injection with Sodium Chloride Injection to a concentration of 100mg per mL.
Uniformity of dosage units á905ñ: meets the requirements.
pHá791ñ: between 4.0and 5.5,in a solution (1in 50).
Other requirements— It meets the requirements under Injections á1ñ.
Assay— Transfer about 100mg of Floxuridine for Injection,accurately weighed,to a 250-mLvolumetric flask,dissolve in and dilute with potassium hydroxide solution (1in 180)to volume,and mix.Transfer 5.0mLof this solution to a 100-mLvolumetric flask,dilute with potassium hydroxide solution (1in 180)to volume,and mix.Concomitantly determine the absorbances of this solution and a Standard solution of USP Floxuridine RS,in the same medium having a known concentration of about 20µg per mL,in 1-cm cells at the wavelength of maximum absorbance at about 268nm,with a suitable spectrophotometer,using potassium hydroxide solution (1in 180)as the blank.Calculate the quantity,in mg,of C9H11FN2O5in the portion of Floxuridine for Injection taken by the formula:
5C(AU/AS),
in which Cis the concentration,in µg per mL,of USP Floxuridine RSin the Standard solution;and AUand ASare the absorbances of the solution from Floxuridine for Injection and the Standard solution,respectively.
Auxiliary Information— Staff Liaison:Behnam Davani,Ph.D.,MBA,Senior Scientist
Expert Committee:(PA7)Pharmaceutical Analysis 7
USP28–NF23Page 828
Phone Number:1-301-816-8394